BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report) shares traded down 5.6% during trading on Wednesday . The stock traded as low as $2.19 and last traded at $2.19. 22,628 shares were traded during trading, an increase of 1,117% from the average session volume of 1,859 shares. The stock had previously closed at $2.32.
BriaCell Therapeutics Stock Performance
The firm has a fifty day simple moving average of $2.84 and a 200 day simple moving average of $3.94. The company has a market capitalization of $1.73 million, a PE ratio of -0.58 and a beta of 1.09.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- P/E Ratio Calculation: How to Assess Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- 5 Top Rated Dividend Stocks to Consider
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Stock Sentiment Analysis: How it Works
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.